Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
Facts & Figures News Career Baxter Worldwide
 
Press Releases

  BAXTER BEGINS CLINICAL TRIALS OF A GROUP B MENINGOCOCCAL MENINGITIS VACCINE

Lucerne, Switzerland 22 March 2001- Baxter International Inc. (NYSE:BAX) announced today that Phase I human clinical trials have begun in Belgi ...

Date: 2001/03/22 » read more

  BAXTER ANNOUNCES PLANS FOR NEW FACILITY FOR PRODUCTION OF RECOMBINANT AND CELL-CULTURE DERIVED VACCINES

Production Expansion Sets the Stage for Significant Growth in Vaccines Business Baxter Expects to Achieve 2001 Earnings Growth in Mid-Teens, Sa ...

Date: 2001/03/07 » read more

  BAXTER RECEIVES APPROVAL FOR NEISVAC-C MENINGOCOCCAL VACCINE IN THE UNITED KINGDOM

Deerfield, Ill. and London, July 19, 2000 -- Baxter’s Hyland Immuno business announced today that the United Kingdom (U.K.) Medicines Control A ...

Date: 2000/07/19 » read more

  Play "Baxter Barney" and protect the kids!

Be baxter barney and vaccinate all the kids with the right vaccines to protect them from ticks or viruses falling down. ...

Date: 2000/06/28 » read more

  BAXTER COMPLETES ACQUISITION OF NORTH AMERICAN VACCINE

DEERFIELD, Ill. and COLUMBIA, Md., June 26, 2000 -- Baxter International Inc. (NYSE:BAX) and North American Vaccine, Inc. (AMEX:NVX) announced ...

Date: 2000/06/26 » read more

  Tick Animation II



Date: 2000/06/18 » read more

  Tick Animation



Date: 2000/06/17 » read more

 
« previous   1 | 2 | 3   next »
 
 
  » find


 

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,